CRESCENT BIOPHARMA, INC. (CBIO) earnings date
Mar 31, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 17 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | before open | 30 | 8-K |
| Q1 FY2026 | Wed, Apr 29, 2026 | after close | 29 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Jul 31, 2025 | before open | 31 | 8-K |
| Q1 FY2025 | Wed, Jun 18, 2025 | after close | 79 | 8-K |
| Q1 FY2024 | Mon, May 6, 2024 | after close | 36 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027 Multiple Phase 2 studies of sacituzumab tirumotecan (sac-TMT) in combination with CR-001 ongoing in China led by partner, Kelun-Biotech, with initi" exhibit |
| Q3 FY2026 | "Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027." exhibit |
| Q3 FY2026 | "Crescent is on track to report initial monotherapy data from ASCEND in the first quarter of 2027, including:" exhibit |
| Q3 FY2026 | "Crescent is on track to report initial data from hundreds of patients in mid-2027 (Q2/Q3)." exhibit |
| Q3 FY2026 | "Initial data from a study in patients with locally advanced or metastatic NSCLC are expected in mid-2027 (Q2/Q3)." exhibit |
| Q2 FY2026 | "Document Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2 trial in NSCLC, first ADC combination study in Kelun-Biotech collaboration, underway in China Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China; Phase 1/2 global trial of CR-002, a PD-L1-targeted ADC, on track to initiate in second " exhibit |
| Q2 FY2026 | "“Our recent financing extends our expected cash runway into the second half of 2028, beyond key catalysts, strengthening our balance sheet as we work to deliver transformative therapies for people living with cancer.”" exhibit |
| Q2 FY2026 | "Crescent is on track to submit an IND application to the U.S. Food and Drug Administration (FDA) for CR-002 in mid-2026 to support the initiation of a global Phase 1/2 trial in solid tumors in the second half of 2026, with proof-of-concept data expected in the second half of 2027." exhibit |
| Q2 FY2026 | "A Phase 1/2 trial of CR-003 (also known as SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the 2 first quarter of 2027." exhibit |
| Q2 FY2026 | "A Phase 1/2 combination trial of CR-003 and CR-001 is expected to initiate in the first half of 2027, with initial data anticipated by year-end 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CBIO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CBIO
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CBIO/"><img src="https://veritasdata.dev/embed/CBIO.svg" alt="CBIO earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CBIO/)
Script
<script async src="https://veritasdata.dev/embed/CBIO.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CBIO"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.